Invitae Releases Data Use Transparency Report, Demonstrating Impact of Patient Data on Genetic Research

Invitae Releases Data Use Transparency Report, Demonstrating Impact of Patient Data on Genetic Research

– Invited to report on the secondary use of patient data, demonstrating the true impact of anonymized patient data on the advancement of precision medicine –

– Company Achieves Over 1 Million ClinVar Submissions to Advance Science and Patient Care –

SAN FRANCISCO, December 7, 2022 /PRNewswire/ — Invite (NYSE: NVTA), a leading medical genetics company, today announced the release of its Data Use Impact and Transparency Report, which details how the company used anonymized data from patients to advance precision medicine. Although many companies collect patient data, they do not disclose how that data is used. Invitae is leading the industry in releasing this report, the first of its kind, on how it used anonymized patient data for secondary data research in 2021.

Unlike most companies, Invitae offers patients the choice of whether or not to allow access to their anonymized data for research purposes. As a company founded on the principles that patients own and control their data and that data is most valuable when shared, this report demonstrates how Invitae upholds these principles in a way that honors patient intent. with the ultimate goal of advancing the science of genomics and precision medicine.

“For precision medicine to advance and real-world evidence to matter, patients must be able to trust that the companies accessing and sharing their data are only working with trusted partners who are also committed to advance science,” said Deven McGraw, responsible for stewardship and data sharing at Invitae. “Being transparent about how we use data is essential not only to earn that trust, but also to demonstrate the impact patients can have on the advancement of science and medicine by sharing access to their data.”

McGraw continued, “It’s time for all companies that generate, collect, use and share anonymized patient data to let patients know how their data is being used and see the impact it has. In a culture of diminishing trust, transparency is no longer an option. It’s essential.

With a database of over 2 million tested individuals worldwide that is available to researchers to access anonymized data from these individuals, Invitee’s research is critical to understanding the prevalence of genetic changes responsible for a wide range of hereditary diseases, develop new therapeutics and identify people likely to benefit from targeted and precision therapies. In 2021, patient data enabled the company to advance important research initiatives and achieve the following goals:

  • Improved internal processes and test quality: Invitae uses the data generated by genetic testing to confirm that our tests meet applicable quality and validity standards, to ensure the improvement of our products, and to advance the science of genetic testing.
  • Advancing the Science of Genetics: Anonymized data from some people tested by Invitae has informed a range of research on medical conditions, including contributions to 38 peer-reviewed publications in 10 health fields, 36 posters covering 11 health topics, and 21 abstracts in the framework of the proceedings of more than 22 scientific conferences.
  • Advance the development of new treatments:
    To help accelerate access to testing and the development and use of gene-based therapies, Invite have proposed “sponsored” testing programs in which patients agree to allow biopharmaceutical companies access to their anonymized data obtained through free genetic testing. In 2021, Invite worked with 31 biopharmaceutical companies to offer 47 sponsored testing programs. In addition, Invite worked with 15 biopharmaceutical partners to lead clinical trial outreach initiatives covering 17 medical conditions.
  • Advancing science-based policy: Based on the analysis of its test data, Invitae developed educational materials and distributed them to policy makers considering the development of legislation to expand access to pediatric genetic testing.

A new stage for open data
Further demonstrating the importance of patient data sharing, Invite recently hit the milestone of over one million ClinVar Submissions. VarClin is a National Institutes of Health Genetic Variant Database that serves as a global resource for sharing interpretations of different genetic variants. VarClin allows test labs and researchers to compare results, helping to broaden the collective understanding of each variant. As the main contributor to this database, Invite sees this milestone as a testament to the company’s founding principle that genetic data is most valuable when shared. Currently, Invite contributed more variants than the next top 16 contributors to VarClin combined.

“Patients need the science of genetics to advance as quickly as possible,” McGraw said. “For this to happen, scientists need to share the data that informs their interpretation with their peers. This milestone shows that we are committed to advancing the role that genetic understanding can play in helping patients who need treatment and cures.

“This report, the first of its kind, is an important first step towards transparency, and is something that should be standard practice for the genetic diagnostics industry as a whole,” said Andrea Downing, co-founder of The Light Collective. “Invitae is making significant strides to lead the industry in accountability to patient communities.”

To learn more, you can download the full report here.

About Invite
Invite Company (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information to traditional medicine to improve health care for billions of people. Guests The goal is to consolidate genetic testing from around the world into one service with better quality, faster turnaround times and lower prices. For more information, visit the company’s website at

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s belief that it is leading the industry by issuing a first-of-its-kind report. how it used identified patient data for secondary data research; the company’s beliefs regarding the importance of this report and transparency regarding the use of the data; and the benefits of the company’s research and use of anonymized patient data. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those reported and should not be relied upon as an indication of future performance. These risks and uncertainties include, but are not limited to: the company’s loss history; the company’s ability to be competitive; the company’s inability to effectively manage growth; the company’s need to evolve its infrastructure in anticipation of demand for its testing and to increase demand for its testing; the company’s ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, data loss and other disruptions; the laws and regulations applicable to the company’s activity; and other risks disclosed in the company’s filings with the Securities and Exchange Commission, including the risks disclosed in the company’s quarterly report on Form 10-Q for the quarter ended September 30, 2022. These forward-looking statements speak only as of the date hereof, and Invite The Company disclaims any obligation to update these forward-looking statements.

Renee Kelley
[email protected]
(628) 213-3283

SOURCE Invite Corporation

#Invitae #Releases #Data #Transparency #Report #Demonstrating #Impact #Patient #Data #Genetic #Research

Leave a Comment

Your email address will not be published. Required fields are marked *